Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
- Tuesday, January 17, 2023, 7:04
- Finance
- Add a comment
— Designation Marks Entry Point into MHRA’s Innovative Licensing and Access Pathway (ILAP) Program in the UK — DUBLIN, Jan. 17, 2023 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (nemvaleukin), the company’s investigational, novel engineered…
About the Author
adminasapcorp has written 41766 stories on this site.